ACTION: On March 25, 2009, Roche Investments USA Inc., a member of the Roche Group, completed its tender offer for Genentech, Inc. (“DNA”) Common Shares. The acquisition of Genentech, Inc. was completed via short form merger on March 26, 2009. As a result, outstanding DNA Common Shares will be converted into $95.00 Cash.
This action will be coordinated with the Options Clearing Corporation.
CATEGORY: Cash Settlement
EQUITY SYMBOL: Genentech, Inc. (“DNA”)
ONE CHICAGO SYMBOL: DNA1C will be de-listed
CME FUTURES SYMBOL: DN will be de-listed
MULTIPLIER: 100 (e.g., 1.00 equals $100.00)
EFFECTIVE DATE: Monday, March 30, 2009
NEW DELIVERABLE PER CONTRACT: $9,500.00 ($95.00 x 100)
APPLICABLE CONTRACT MONTHS: April, May, June, and September 2009
SETTLEMENT PRICES AND POSITIONS: The maturity date for all DNA1C Security Futures will be accelerated to March 30, 2009.
NOTES: The forecasted effect of the upcoming corporate event on each clearing firms’ positions can be viewed in infopac in the Corporate Event Initial Forecast Report (ONE712), the Corporate Event Final Forecast Report (ONE713), and the Corporate Event Forecast Audit Report (CPDBU710).
If you have any questions regarding the information provided in the document, please call CME Clearing risk management hotline at (312) 648-3888.